Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy, such
as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing
or die. Combining bevacizumab with docetaxel may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying bevacizumab and docetaxel to see how well
they work compared to bevacizumab alone in treating patients with metastatic pancreatic
cancer.